Form D · Pharmaceuticals

GELESIS HOLDINGS, INC.

Boston, MA · CIK 0001805087

Offering snapshot reported Aug 24, 2022 · SEC filing

Reported sold
$576K
Offering amount: $50.6M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 11, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 24, 2022Initial$575,684No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-456915
Total Offering Amount represents the aggregate of (i) up to $50,000,000 of common stock and (ii) 355,361 shares of common stock issued as consideration for entering into the Purchase Agreement. See the Issuer's Current Report on Form 8-K filed on 8/12/22.

Source: Form D, filed Aug 24, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
David Abraham Executive
Alison Bauerlein Director
Kathryn Cavanaugh Director
Elaine Chiquette Executive
Clayton Christopher Director
Paul Fonteyne Director
Raju Kucherlapati Director
Harry L. Leider Executive
Elliot Maltz Executive
David Pass Executive
Dominic Perks Director
Alessandro Sannino Executive
Jane Wildman Director
Yishai Zohar Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
501 Boylston Street, Suite 6102
Boston, MA, 02116